| Literature DB >> 34411002 |
Grégory Noël1, Mireille Langouo Fontsa1, Soizic Garaud1, Pushpamali De Silva1, Alexandre de Wind2, Gert G Van den Eynden1,3, Roberto Salgado3, Anaïs Boisson1, Hanne Locy4, Noémie Thomas1, Cinzia Solinas1, Edoardo Migliori1, Céline Naveaux1, Hugues Duvillier1,5, Sophie Lucas6, Ligia Craciun2, Kris Thielemans4, Denis Larsimont2, Karen Willard-Gallo1.
Abstract
We previously demonstrated that tumor-infiltrating lymphocytes (TIL) in human breast cancer sometimes form organized tertiary lymphoid structures (TLS) characterized by CXCL13-producing T follicular helper (Tfh) cells. The present study found that CD4+ Tfh TIL, CD8+ TIL, and TIL-B, colocalizing in TLS, all express the CXCL13 receptor CXCR5. An ex vivo functional assay determined that only activated, functional Th1-oriented Tfh TIL (PD-1hiICOSint phenotype) provide help for immunoglobulin and IFN-γ production. A functional Tfh TIL presence signals an active TLS, characterized by humoral (immunoglobulins, Ki-67+ TIL-B in active germinal centers) and cytotoxic (GZMB+CD8+ and GZMB+CD68+ TIL plus Th1 gene expression) immune responses. Analysis of active versus inactive TLS in untreated patients revealed that the former are associated with positive clinical outcomes. TLS also contain functional T follicular regulatory (Tfr) TIL, which are characterized by a CD25+CXCR5+GARP+FOXP3+ phenotype and a demethylated FOXP3 gene. Functional Tfr inhibited functional Tfh activities via a glycoprotein A repetitions predominant (GARP)-associated TGF-β-dependent mechanism. The activity of tumor-associated TLS was dictated by the relative balance between functional Tfh TIL and functional Tfr TIL. These data provide mechanistic insight into TLS processes orchestrated by functional Th1-oriented Tfh TIL, including TIL-B and CD8+ TIL activation and immunological memory generation. Tfh TIL, regulated by functional Tfr TIL, are an expected key target of PD-1/PD-L1 blockade.Entities:
Keywords: Adaptive immunity; Breast cancer; Immunology; Oncology; Th1 response
Mesh:
Substances:
Year: 2021 PMID: 34411002 PMCID: PMC8483751 DOI: 10.1172/JCI139905
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808